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This retrospective study reports the data of sofosbuvir-based 
anti-hepatitis C virus treatment in 24 candidates and 24 recip-
ients of liver transplantation coinfected with human immuno-
deficiency virus. Sustained virologic response was cumulatively 
85% (90% and 100% in those treated with optimal schedules 
pre- and posttransplant, respectively).
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In persons living with human immunodeficiency virus 
(PLWHIV), orthotopic liver transplantation (OLT) has produced 
excellent results when liver disease was not due to active hepati-
tis C virus (HCV) infection [1]. Human immunodeficiency virus 
(HIV)/HCV-coinfected patients with decompensated cirrhosis 
have lower survival rates (less than 1 year), mainly because of 
higher mortality while on the list [2]. A meta-analysis of all the 
reported series demonstrated that in HCV/HIV-coinfected per-
sons, survival at 5 years is 50%–55%, which is poorer than in 
HCV-monoinfected patients, mainly due to the more aggressive 
recurrence of HCV and consequent graft loss and death [1].
The most effective factor influencing OLT outcome is success-
ful treatment of HCV recurrence [1]. Interferon (IFN)-based 
therapies in coinfected OLT candidates and recipients showed 
low efficacy and high toxicity [3]. In contrast, sofosbuvir (SOF)-
based therapies have showed high efficacy and tolerability in 
both OLT candidates and recipients [4]. So far, small series data 
in HIV/HCV-coinfected persons have been published, cumula-
tively reporting treatment in 13 OLT candidates and 48 recip-
ients [5–10]. The aim of this study was to assess the impact of 
SOF-based anti-HCV, all oral treatment on OLT in PLWHIV.
METHODS
This retrospective, multicenter study involved 5 Italian Liver 
Transplant Centers with an active program of OLT in PLWHIV. 
All HIV/HCV-coinfected patients on the waiting list for OLT 
or already transplanted who consecutively started any IFN-
free SOF-based therapy from June 2013 to January 2016 were 
included. Indications for OLT were HCV-related decompensated 
cirrhosis with a model for end-stage liver disease (MELD) above 
15 or hepatocellular carcinoma (HCC) within the Milan criteria.
Treatment combinations changed over time according to 
drug availability: SOF was available for compassionate use since 
2013, and daclatasvir (DCV) was available for compassion-
ate use since December 2014. Thereafter, marketed SOF was 
available for clinical use since December 2014, and marketed 
DCV was available for clinical use since February 2015; SOF/
ledipasvir (LDV) fixed-dose combination was available since 
May 2015.
Sustained virologic response at 12 weeks (SVR12) was defined 
by undetectable HCV-ribonucleic acid (RNA) 12 weeks after 
treatment withdrawal. The rate of SVR12 was assessed with an 
intention-to-treat (ITT) SVR12 approach, defined as the rate of 
SVR12 among all the patients who took at least 1 dose of SOF. In 
addition, a modified ITT (mITT) SVR12 was assessed, defined 
as the rate of SVR12 among the patients who took at least 1 
dose of SOF, excluding those who stop the scheduled regimen 
for nonvirological reasons.
Hepatitis C virus genotype was assessed by Inno LIPA HCV 
2.0; HCV-RNA was measured with Cobas TaqMan versus 
2 Roche Diagnostics or Abbott RealTime HCV assay. Next-
generation sequencing (detection threshold: 15%) to identify 
treatment-emergent substitutions in NS3, NS5A, and NS5B HCV 
genomic regions was performed in case of virological failure.
Hepatitis C virus RNA as well as liver function tests (includ-
ing international normalized ratio, bilirubin, albumin, and 
creatinine) were performed at baseline, every 4 weeks during 
the treatment, at the end of therapy, and 4 and 12 weeks after 
treatment withdrawal. Human immunodeficiency virus RNA 
and T lymphocyte CD4+ and CD8+ cell counts were measured 
at baseline and every 12 weeks thereafter.
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Levels of immunosuppressive drugs were monitored during 
treatment according to local protocols. The study was con-
ducted in accordance with the ethical standards of the Helsinki 
Declaration, informed consent was obtained from each partici-
pant, and the study was approved by the local ethical committee 
of each participating center.
RESULTS
Study Population
Forty-eight patients were included in this study: 24 treated while 
on the waiting list and 24 after OLT. Patients’ demographic and 
clinical features are summarized in Table 1.
Treatment
The suboptimal regimen of SOF and ribavirin (RBV) was used 
in 10 patients pre-OLT and 9 patients post-OLT. The remaining 
patients were treated with SOF in combination with an NS5A 
inhibitor, with or without RBV: in the pre-OLT setting, 12 used 
DCV and 2 used LDV; in the post-OLT setting, 9 used DCV 
and 6 used LDV. Only 7 patients were treated for 12 weeks (2 in 
the pretransplant cohort), and the remaining 41 patients were 
treated for at least 24 weeks (in 3 candidates, the therapy lasted 
until OLT). The antiretroviral regimens were mostly based on 
integrase inhibitors (79.2%), and 40% were on tenofovir dis-
oproxil fumarate. Twelve of 48 (25%) subjects were switched 
Table 1. Characteristics of the Study Population and Treatment Response in 48 HIV-HCV-Coinfected Patients Treated Pre- and Postliver Transplant
Characteristics Patients Treated Pretransplant (N = 24) Patients Treated After Transplant (N = 24)
Age year median (IQR) 51 (50–52) 52.5 (49–54)
Gender, male N (%) 18 (75%) 20 (83%)
HCV Genotype
 1a 11 8
 1b 4 6
 2 1 0
 3 4 3
 4 4 7
HCV-RNA log10 IU/mL median (IQR) 5.64 (4.48–6.02) 6.81 (6.04–7.08)
Experienced
PEG-IFN + RBV 15 (62%) 17 (71%)
PEG-IFN + RBV + NS3I 0 1 (4%)
Time from OLT weeks, median (IQR) – 49 (5–142)
CD4 cell/mm3 median (IQR) 356 (239–497) 342 (236–580)
HIV-RNA undetectable N (%) 24 (100%) 22 (92%)
Cirrhosis n (%) with HCC N (%) 24 (100%) 6 (25%) 12 (50%)
MELD median (IQR) 16 (12–20) 8 (6–10)
MELD >18 7 (29%) 1 (4%)
Child Pugh B 16 (67%) 5 (21%)
Child Pugh C 4 (25%) 2 (10%)
Immunosuppression based on tacrolimus N (%) _ 19 (79%)
ART, N (%)
Including INSTI 17 (71%) 21 (87%)
Including tenofovir 10 (42%) 9 (37%)
Anti-HCV treatment used
SOF + RBV 10 (40%) 9 (37%)
SOF + DCV ± RBV 12 (50%) 9 (37%)
SOF/LDV ± RBV 2 (10%) 6 (25%)
Duration of SOF 12/24/>24 weeks 3/18/3 4/20/0
SVR12 ITT (overall) 19/24 (79%) 22/24 (92%)
SVR12 mITT (overall) 19/22 (87%) 23/24 (96%)
SOF + RBV SVR ITT 7/103a (70%) 8/9 3a (89%)
SOF + RBV SVR mITT  7/103a (70%) 8/9 3a (89%)
SOF + DCV ± RBV ITT 11/122b (92%) 8/9 4c (89%)
SOF + DCV ± RBV mITT 11/11 (100%) 8/8 (100%)
SOF/LDV ± RBV ITT 1/21d 6/6 (100%)
SOF/LDV ± RBV mITT 1/1 6/6 (100%)
Abbreviations: ART, antiretroviral therapy; DCV, daclatasvir; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; INSTI, integrase inhibitors (raltegravir 
and dolutegravir); ITT, intention to treat; IQR, interquartile range; LDV, ledipasvir; MELD, model for end-stage liver disease; mITT, modified intention to treat (nonvirological failure excluded); 
NS3i, first-generation NS3 inhibitors (ie, boceprevir or telaprevir); OLT, orthotopic liver transplantation; PEG-IFN, pegylated interferons alpha 2a or 2b; RBV, ribavirin; RNA, ribonucleic acid; 
SOF, sofosbuvir; SVR, sustained virologic response (ie, HCV-RNA undetectable 12 weeks after anti-HCV treatment withdrawal). 
Note: Reasons for nonresponse were as follows: a, virological relapse; b, HCC progression withdrawn from waiting list and stopped anti-HCV at 12 weeks with relapse; c, death due to 
graft dysfunction (vanishing bile duct syndrome) with undetectable HCV-RNA on treatment; d, death due to intracranial bleeding with undetectable HCV-RNA on treatment.
BRIEF REPORT • OFID • 3
from previous anti-HIV treatment before starting anti-HCV 
therapy because of potential drug-drug interactions. The 
immunosuppressive treatment included tacrolimus in 19 OLT 
recipients (79.2%) and cyclosporin in 5 (20.8%).
Hepatitis C Virus Virologic Response
The SVR12 was achieved by 41 of 48 subjects (85.4%): 19 of 24 
(79.2%) pre-OLT and 22 of 24 (91.7%) post-OLT. There were 
4 virological failures: 3 relapses in the pre-OLT group and 1 
relapse in the post-OLT group; all of these patients were treated 
with a dual SOF and RBV regimen and were infected by HCV 
genotype 1. Results are reported in detail in Table 1.
Cumulatively, 19 patients started a suboptimal therapy 
according to the EASL guidelines (SOF + RBV): in these indi-
viduals, ITT SVR12 and mITT SVR12 rates were both 79% 
(both 70% pre-OLT and 89% post-OLT). In the remaining 29 
patients treated with optimal combinations according to the 
EASL guidelines, ITT SVR12 was 90% and mITT SVR12 100% 
(both in pre-OLT and post-OLT).
No clear indications about when to stop treatment after 
OLT were available during the majority of pre-OLT treatments. 
Therapy was initiated while patients were on the waiting list and 
completed according to the programmed schedule after OLT in 4 
patients, and all patients achieved SVR. In 1 patient, SOF and RBV 
treatment was stopped on the day of liver transplantation after 20 
weeks of treatment and 12 weeks after his first undetectable HCV-
RNA, but this patient relapsed after OLT. No resistance-associated 
substitutions were registered after treatment failure.
Safety
During and after anti-HCV treatment, no HIV breakthroughs 
were observed; however, in 1 patient, a treatment failure was 
registered after OLT. Likewise, no clinically significant decrease 
in T lymphocyte CD4+ cell count was noted.
No serious treatment-related adverse events were recorded. 
Ribavirin was given with an escalating schedule starting from 
600 mg daily in 37 of 48 subjects: 5 of 37 showed anemia (hemo-
globin, <10.5  g/dL). Infections, either bacterial or viral, were 
observed in 4 subjects: 1 had herpetic cheratitis, 1 had sepsis, 1 
had prostatitis, and 1 had a urinary tract infection.
Liver-related complications were seen in 3 individuals: 
1 developed spontaneous bacterial peritonitis, 1 developed 
hepatic encephalopathy, and 1 developed jaundice (even 
40
35
30
25
20
15M
E
L
D
 s
co
re
10
5
Pre Tx
Pt n 1
Pt n 7
Pt n 13
Pt n 19
Pt n 2
Pt n 8
Pt n 14
Pt n 20
Pt n 3
Pt n 9
Pt n 15
Pt n 21
Pt n 4
Pt n 10
Pt n 16
Pt n 22
Pt n 5
Pt n 11
Pt n 17
Pt n 23
Pt n 6
Pt n 12
Pt n 18
Pt n 24
EOT SVR12
0
Figure 1. Model for end-stage liver disease (MELD) scores measured pretreat-
ment (Pre Tx) at the end of treatment (EOT) and 12 weeks after treatment end of 
treatment (12 weeks post-EOT) in the 24 patients treated while on the waiting list 
for liver transplantation. SVR12, sustained virologic response at 12 weeks. 
Table 2. Flow Diagram for the Cohort of HIV-HCV-Coinfected Patients Treated Pretransplant
All Patients 24
Treatment SOF ± RBV 24 Weeks SOF + DCV ± R 
12–24 Weeks
SOF + LDV ± RBV 
12–24 Weeks
Number of patients 10 12 2
Treatment response SVR 24: 7 NR: 3 SVR24: 11 D/O: 1a SVR 24: 1 D/O: 1b
Patients status on January 31, 2017 
(median follow up after treatment 
withdrawal up 18 months, IQR 
14–20 months)
Death 1b
Transplant without HCV 
recurrence
7 5 1 1b
Transplant with HCV 
recurrence
1
SVR24 and delisted alive with 
MELD <10
6
NR and delisted 1c 1a
NR and on the waiting list 
with MELD >15
1
Abbreviations: DCV, daclatasvir; D/O, drop out; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; LDV, ledipasvir; MELD, model for end-stage liver disease; 
NR, nonresponder; RBV, ribavirin; RNA, ribonucleic acid; SOF, sofosbuvir; SVR24, sustained virologic response 24 weeks posttreatment withdrawal.
aWithdrawn from treatment and liver transplant list 12 weeks after treatment initiation for progression of hepatocellular carcinoma relapser after anti-HCV treatment (HCV genotype 3); 
treated with sorafenib on January 31, 2017, 17 months after treatment withdrawal, alive without progression of hepatocellular carcinoma with detectable HCV-RNA.
bTreated with SOF and LDV for 12 weeks before and after transplant; died for cerebral hemorrhage 1 month after liver transplant while on SOF + LDV with on treatment response.
cWithdrawn from liver transplant list for “de novo” hepatocellular carcinoma outside of Milan criteria; nonresponder to SOF and RBV for 24 weeks; on January 31, 2017, 19 months after 
treatment withdrawal, alive and on sorafenib with progession of hepatiocellular carcinoma and liver decompensation MELD 24.
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though the patient was receiving atazanavir). A  renal insuffi-
ciency grade of III or more was not observed during or after 
treatment. Cyclosporin toxicity was observed in 2 subjects: 1 
showed mild neurologic toxicity, whereas the other had seizures 
promptly resolved after specific treatment and cyclosporin dose 
adjustment.
Liver Disease-Related Outcomes
Among the 24 subjects who started the treatment while on the 
waiting list, 2 were withdrawn: 1 for HCC progression, and 1 
for HCC “de novo” occurrence outside from the Milan crite-
ria. None of them achieved the SVR12. Six (25%) subjects were 
withdrawn from the waiting list after the achievement of SVR12 
because they maintained a MELD value below 15 for more than 
6 months (delta MELD at SVR12 −5, interquartile range −2 to 
−6). Figure 1 reports change of MELD score in patients treated 
pretransplant before, during, and after treatment.
Fifteen patients underwent transplantation: 1 died as a result of 
cerebral hemorrhage and could not be considered as a candidate 
for viral eradication, and 12 achieved SVR12. As mentioned, 1 
showed post-OLT recurrence after SOF and RBV withdrawal at 
transplantation. Another one did not respond to SOF and RBV 
and is currently on re-treatment with SOF/LDV; he is still on the 
waiting list. Table 2 reports the flow diagram of the 24 patients 
treated before liver transplantation and their status as observed 
on January 31, 2017. Among the 24 subjects who started treat-
ment after OLT, 22 are still alive, and 1 died from liver failure 
due to vanishing bile duct syndrome after acute rejection (HCV-
RNA was undetectable during his last control visit).
DISCUSSION
Sofosbuvir-based treatment was safe and effective in HCV/
HIV-coinfected patients who were OLT candidates or recip-
ients: SVR rates were higher than 90% in both settings when 
optimal treatment regimens were used. Data of 13 patients 
treated pre-OLT have been published: SVR was observed in 9 
of 10 patients treated with optimal therapy (90%) and in 1 of 
3 (33.3%) patients treated with SOF and RBV. Six small series 
reported the data of 48 patients treated post-OLT: the SVR12 
rate was 90%, but it topped at 100% when evaluating only the 28 
patients treated with optimal regimens [5–10]. These and our 
results confirm the data observed in HCV-monoinfected indi-
viduals in the same settings [4].
Twenty-five percent of OLT candidates were withdrawn from 
the list: this proportion is similar to that observed in other 
cohorts of patients treated pre-OLT [11]. In addition, the treat-
ment schedule was completed post-OLT in 4 patients without 
safety or efficacy issues, confirming anecdotal data observed in 
persons without HIV infection [11].
Two patients of the 6 candidates with a HCC showed tumor 
progression. This rate was not different from that observed in 
untreated HCV-HIV-coinfected patients [1]. Nevertheless, 
taking into consideration the recently emerged data on relapse of 
HCC in patients treated with oral anti-HCV drugs [12], pre-OLT 
treatment of these patients should be considered with caution.
CONCLUSIONS
In conclusion, SOF-based anti-HCV treatment is safe and effec-
tive pre- and post-OLT, and it has the potential to improve the 
outcome of OLT in HCV/HIV-coinfected patients. Pre-OLT 
treatment should be strongly considered for HIV-infected 
patients because of the higher wait-list mortality due to pro-
gression of liver disease [2]; nevertheless, treatment could be 
delayed posttransplant in patients with HCC and compensated 
liver disease.
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